Exhibit 99.1 Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL Consolidated Financial Statements Years Ended December 31, 2021 and 2020




---

Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL  Table of Contents Years Ended December 31, 2021 and 2020  PageIndependent Auditors Report


1Consolidated Financial StatementsConsolidated Balance Sheets


3Consolidated Statements of Operations


4Consolidated Statements of Changes in Members Equity


5Consolidated Statements of Cash Flows


6Notes to Consolidated Financial Statements


7




---

LOGO Independent Auditors Report To the Board of Managers of Gemino Healthcare Finance, LLC and
Subsidiary Opinion We have audited the consolidated
financial statements of Gemino Healthcare Finance, LLC and Subsidiary d/b/a SLR Healthcare ABL (the Company), which comprise the consolidated balance sheets as of December 31, 2021 and 2020, and the related consolidated statements of
operations, changes in members equity and cash flows for the years then ended, and the related notes to the consolidated financial statements. In
our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020 and the results of its operations and its cash flows for the years
then ended in accordance with accounting principles generally accepted in the United States of America (GAAP). Basis for Opinion We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those
standards are further described in the Auditors Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the Company and to meet our other ethical responsibilities, in
accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion. Responsibilities of Management for the Consolidated Financial Statements Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with GAAP, and for the design,
implementation and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error. In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate,
that raise substantial doubt about the Companys ability to continue as a going concern within one year after the date that the financial statements are available to be issued. Auditors Responsibilities for the Audit of the Consolidated Financial Statements Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether
due to fraud or error, and to issue an auditors report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS
will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions,
misrepresentations or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the
consolidated financial statements. Baker Tilly US, LLP, trading as Baker Tilly, is a member of the global network of Baker Tilly International Ltd., the
members of which are separate and independent legal entities. © 2020 Baker Tilly US, LLP  1




---

In performing an audit in accordance with GAAS, we:  

Exercise professional judgment and maintain professional skepticism throughout the audit.  

Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to
fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.  

Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are
appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Companys internal control. Accordingly, no such opinion is expressed.  

Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting
estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.  

Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise
substantial doubt about the Companys ability to continue as a going concern for a reasonable period of time. We are required to
communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.  LOGO Philadelphia, Pennsylvania February 18, 2022  2




---

Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL  Consolidated Balance Sheets December 31, 2021 and 2020  2021


2020AssetsAssetsCash and cash equivalents

$
3,256,256


$
10,356,890Loans receivable, net


81,603,569



39,340,360Accrued interest receivable


664,127



627,981Intangible asset - trade name






2,800,000Goodwill


5,663,531



5,663,531Furniture and equipment, net


14,319



21,100Other assets


72,954



71,327Total assets

$
91,274,756


$
58,881,189Liabilities and Members EquityLiabilitiesCredit facility, net

$
59,398,378


$
24,201,884Accounts payable and accrued expenses


2,491,180



2,239,801Dividend payable


529,058



529,029Total liabilities


62,418,616



26,970,714Members equityUnits, $1,000 par value, issued and outstanding 35,270 and 35,270, respectively


32,820,783



32,820,783Accumulated deficit


(3,964,643
)


(910,308
)Total members equity


28,856,140



31,910,475Total liabilities and members equity

$
91,274,756


$
58,881,189 See notes to consolidated financial statements  3




---

Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL  Consolidated Statements of Operations Years Ended December 31, 2021 and 2020  2021


2020Interest income:Interest income

$
5,583,832


$
7,092,079Interest expense


1,634,855



2,305,418Net interest income


3,948,977



4,786,661Provision for loan losses


426,428



(726,251
)Net interest income after provision for loan losses


3,522,549



5,512,912Other income


4,468,588



3,275,372Operating expenses:Compensation and benefits


3,819,816



3,823,694Depreciation and amortization


2,811,730



14,338General and administrative


697,811



661,336Total operating expenses


7,329,357



4,499,368Net income

$
661,780


$
4,288,916 See notes to consolidated financial statements  4




---

Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL  Consolidated Statements of Changes in Members
Equity Years Ended December 31, 2021 and 2020  Balance at December 31, 2019

$
31,339,970Capital distributions


(2,186
)Dividends declared


(3,716,225
)Net income


4,288,916Balance at December 31, 2020

$
31,910,475Capital distributions


Dividends declared


(3,716,115
)Net income


661,780Balance at December 31, 2021

$
28,856,140 See notes to consolidated financial statements  5




---

Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL  Consolidated Statements of Cash Flows Years Ended December 31, 2021 and 2020  2021


2020Cash Flows from Operating ActivitiesNet income

$
661,780


$
4,288,916Adjustments to reconcile net income to net cash provided by operating activities:Depreciation


11,730



14,338Amortization of intangible asset - trade name


2,800,000



Amortization of deferred origination fees and costs


(590,858
)


(346,265
)Amortization of debt issuance costs


229,084



228,034Provision for loan losses


426,428



(726,251
)Changes in assets and liabilities:(Increase) decrease in accrued interest receivable


(36,146
)


431,123(Increase) decrease in other assets


(1,627
)


11,986Increase in deferred origination fees and costs


507,863



505,850Increase (decrease) in accounts payable and accrued expenses


251,379



(21,356
)Net cash provided by operating activities


4,259,633



4,386,375Cash Flows from Investing Activities(Increase) decrease in loans receivable, net


(42,606,642
)


72,193,946Purchase of furniture and equipment


(4,949
)


(6,597
)Net cash (used in) provided by investing activities


(42,611,591
)


72,187,349Cash Flows from Financing ActivitiesProceeds from (repayments of) credit facility, net


35,000,000



(64,000,000
)Debt issuance costs paid


(32,590
)


(19,618
)Dividends paid


(3,716,086
)


(3,716,275
)Capital distributions






(2,186
)Net cash provided by (used in) financing activities


31,251,324



(67,738,079
)Net (decrease) increase in cash and cash equivalents


(7,100,634
)


8,835,645Cash and cash equivalents, beginning of the year


10,356,890



1,521,245Cash and cash equivalents, end of the year

$
3,256,256


$
10,356,890Supplemental Disclosure of Cash Flow InformationInterest paid

$
1,359,195


$
2,265,221 See notes to consolidated financial statements  6




---

Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL  Notes to Consolidated Financial Statements Years Ended December 31, 2021 and 2020  1.
Description of Business Gemino Healthcare Finance, LLC is a Delaware limited liability company formed in December 2006. In February 2021, the Company filed a d/b/a in
the name of SLR Healthcare ABL (SLR Healthcare). SLR Healthcare is a commercial finance company that originates, underwrites and manages primarily secured, asset-based loans for small and mid-sized
companies operating across the U.S. in the healthcare industry. SLR Healthcares loans are primarily in the form of revolving lines of credit, secured by accounts receivable of the borrowers. The accounts receivable serving as collateral are
primarily third party obligations from government payers, such as Medicare or Medicaid, and commercial insurers. In certain cases, SLR
Healthcare may provide senior term loan financing, including real estate financing to qualified borrowers in addition to a revolving line of credit. Senior term loans, including real estate loans are typically secured by accounts receivable and all
other assets of the borrowers, such as pledges of the stock of the borrowers and real estate. Gemino Healthcare Funding, LLC (Gemino
Funding) is a wholly-owned special purpose limited liability company that purchases and holds certain eligible loans and related property from SLR Healthcare (collectively, the Company). On September 30, 2013, SLR Senior Investment Corp. formerly known as Solar Senior Capital Ltd. (SLR Senior), a Maryland
corporation, acquired a controlling interest in SLR Healthcare. The remaining interest is held by various employees of SLR Healthcare through their investment in Gemino Management Investment, LLC. On January 30, 2020, the World Health Organization declared a global emergency in the wake of the novel coronavirus (COVID-19) outbreak and in March of 2020 declared the outbreak a global pandemic. The outbreak of COVID-19 and its related negative public health developments have
adversely affected workforces, customers, suppliers, economies and financial markets around the world. The Companys ability to execute its business initiatives and strategies, will continue to depend on future developments in the U.S. and
globally, which are uncertain and cannot be predicted, including the duration and further spread of the disease, as well as the severity of the economic downturn or any delay or weakness in the economic recovery. This impact will in part be
dependent on the U.S. government and other actions taken to lessen the health and economic repercussions, such as additional fiscal stimulus, and the effectiveness of past and any future fiscal, monetary and other governmental actions. While the
Company considers these disruptions to be temporary, if they continue, this may have a material adverse effect on the Companys results of future operations.  2.
Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of SLR Healthcare and Gemino Funding. All significant intercompany balances have
been eliminated in consolidation.  7




---

Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL  Notes to Consolidated Financial Statements Years Ended December 31, 2021 and 2020  Use of Estimates The preparation of consolidated financial statements in conformity with generally accepted accounting principles in the United States of
America (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements
and to report amounts of revenues and expenses during the reporting period. Actual results could differ materially from these estimates. The allowance for loan losses represents an estimate that is particularly susceptible to material change. Cash and Cash Equivalents Cash and cash equivalents include funds deposited with financial institutions and short-term, liquid investments in money market accounts with
original maturities of three months or less. Loans Receivable Loans receivable that management has the intent and ability to hold for the foreseeable future or until maturity or payoff are reported at
their outstanding unpaid principal balances less the allowance for loan losses and any deferred fees or costs. Commitment terms of the
Companys financing agreements generally range from two to five years with interest charged on a floating rate basis. Funding under revolving loan commitments is subject to the Companys estimation of the value of the accounts receivable
pledged as collateral. Revenue Recognition Income on loans receivable is recognized using the simple interest method. Revolving loan origination fees and costs are deferred and amortized
on a straight-line basis over the terms of the related loan commitments as an adjustment to interest income on loans. Term loan origination fees and costs are deferred and amortized using either the effective interest method or the straight-line
method over the life of the loan as an adjustment to interest income. The straight-line method may be used for term loan facilities when it approximates the effective interest method. Other fees, such as unused balance and collateral monitoring
fees, are recognized when the services are provided. Termination fees are recognized when a loan is terminated. These other fees are included in other income. The accrual of interest on loans is discontinued at the time the loan is 90 days delinquent unless the loan is secured. Typically, loans are
placed on non-accrual or charged off at an earlier date if collection of principal or interest is considered doubtful. When a loan is placed on non-accrual status, all
interest previously accrued, but not collected, is reversed against current interest income and all future proceeds received will generally be applied against principal or interest, in the judgment of management. Loans are returned to accrual status
when all principal and interest amounts contractually due are reasonably assured. The Company recognizes revenue in accordance with the
Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 606, Revenue from Contracts withCustomers,which outlines a single comprehensive model for entities to use in accounting for
revenue arising from contracts with customers. The core principle of the revenue model is for an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the
entity expects to be entitled in exchange for those goods and services.  8




---

Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL  Notes to Consolidated Financial Statements Years Ended December 31, 2021 and 2020  2.
Summary of Significant Accounting Policiescontinued Revenue Recognitioncontinued ASC 606 is not applicable to financial instruments and, therefore, does not impact the Companys revenues. The Company has evaluated the
nature of its contracts with customers and fully satisfies its performance obligations on its contracts as services are rendered and the transaction prices are typically fixed; they are charged either on a periodic basis or based on activity. Impaired Loans A loan is
considered impaired when, based on current information and events, it is probable that the Company will be unable to collect all amounts due in accordance with the contractual terms of the loan agreement. Loans are evaluated for impairment by the
Company based on an ongoing analysis of each borrowers repayment capacity, the value of the collateral support and the strength of any guarantees. Loans identified as impaired are further evaluated to determine the estimated extent of
impairment. Allowance for Loan Loss The allowance for loan loss represents the Companys recognition of the assumed risks of extending credit. The allowance is maintained at
a level considered adequate to provide for probable losses inherent in the loan portfolio. Management establishes a general portfolio reserve for unimpaired loans based on various factors including historical loss experience, the overall credit
quality of the loan portfolio, economic trends and conditions, and the regulatory environment. The overall credit quality of the
Companys borrowers is reflected in the individual and weighted average credit risk ratings of the loans in the portfolio. Credit risk ratings for each borrower are established based on a number of qualitative and quantitative factors including
an assessment of management and strategy, historical and projected repayment capacity, collateral coverage and performance, financial condition and sponsorship, strength of guarantees and any contingencies. Specific allowances for loan losses on impaired loans are typically measured based on a comparison of the recorded carrying value of the loan
to the present value of the loans expected cash flow using the loans effective interest rate, the loans estimated market price or the estimated fair value of the underlying collateral, if the loan is collateral-dependent combined
with the strength of any guarantee arrangements. Specific allowances are recorded when the discounted cash flows, collateral value, or aggregate market price of the impaired loan is lower than the carrying value of that loan. Loans are charged off when collection is questionable and when the Company can no longer justify maintaining the loan as an asset on the
consolidated balance sheet. Loans qualify for charge off when, after thorough analysis, all possible sources of collection are determined to be insufficient to repay the loan. These include impairment of potential future cash flow, value of
collateral and/or financial strength of guarantors. Recoveries of previous charge-offs are recorded when received. For the years ended December 31, 2021 and 2020, there were no recoveries of previous charge-offs.  9




---

Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL  Notes to Consolidated Financial Statements Years Ended December 31, 2021 and 2020  Goodwill and Intangible Asset Goodwill and intangible asset - trade name arose from the acquisition of the Company on September 30, 2013 (Note 1). Goodwill represents
the excess of the purchase price over the fair value of those acquired net assets. Goodwill is not amortized, but instead is reviewed for impairment annually typically in December of each year or more frequently upon the occurrence of certain events
or substantive changes in circumstances. The Company assesses goodwill for impairment by comparing the carrying value of the Company to its fair value. The Company has the option to perform a qualitative assessment to determine if an impairment is
more likely than not to have occurred. If the conclusion is supported that it is not more likely than not that the fair value is less than its carrying amount, then the Company would not need to perform a quantitative impairment test. If the
conclusion cannot be supported, or if the Company does not elect to do the qualitative assessment, then the Company will perform a quantitative assessment. If a quantitative goodwill impairment assessment is performed, the Company utilizes a
combination of market and income valuation approaches. No impairment of goodwill resulted for the years ended December 31, 2021 and 2020, respectively. The Company assessed its indefinite-lived intangible asset  trade name for impairment by comparing the carrying value of the asset to its
fair value. The fair value of intangible asset - trade name was estimated using the relief from royalty method, which is an income approach based on the present value of royalties the Company would theoretically have had to pay to license the trade
name from a third party. During 2021 as part of the rebranding strategy to change its name via the d/b/a filing to SLR Healthcare ABL, the Company evaluated the trade names indefinite-lived position and elected to change the indefinite-lived
intangible asset  trade name to a finite-lived intangible asset  trade name for the period ending December 31, 2021. Accordingly, the carrying value previously ascribed to the intangible asset  trade name was fully amortized
as of December 31, 2021. For the year ended December 31, 2020, there were no impairments to intangible asset  trade name. Furniture and Equipment Furniture and equipment are recorded at cost, net of accumulated depreciation, and are depreciated on a straight-line basis over their
estimated useful lives ranging from three to five years. Debt Issuance Costs The Company reports origination and other costs related to debt issuances as a direct deduction from the carrying amount of the debt liability.
These expenses are deferred and amortized using either the effective interest method or the straight-line method over the stated life as an adjustment to interest expense. The straight-line method may be used on revolving facilities when it
approximates the effective interest method.  10




---

Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL  Notes to Consolidated Financial Statements Years Ended December 31, 2021 and 2020  Income Taxes The Company is not subject to federal or state income taxes. Members of the Company have elected to report the taxable income or loss on their
individual tax returns. Accordingly, no provision for income taxes has been recorded in the accompanying consolidated financial statements. The Company applies authoritative guidance relating to the accounting for uncertain tax positions. Accordingly, a provision for uncertain tax
positions and related penalties and interest is recognized when it is more-likely-than-not, based on the technical merits, that the tax position will not be realized or sustained upon examination by the
appropriate taxing authority. Management determined there were no tax uncertainties that met the recognition threshold in 2021 and 2020. The Company files both federal and state income tax returns. The Company remains subject to examination by taxing authorities for the years
2018 and after. Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13,Financial Instruments - Credit Losses (Topic 326) to
replace the incurred loss model, which is referred to as the current expected credit loss (CECL) model. The CECL model is applicable to the measurement of credit losses on financial assets measured at amortized cost, including loans
receivable and held-to maturity debt securities. It also applies to off-balance sheet credit exposures including loan commitments, standby letters of credit, financial
guarantees, and other similar instruments. For the assets within the scope of CECL, a cumulative-effect adjustment will be recognized in retained earnings as of the beginning of the first reporting period in which the guidance is effective. This new
standard is effective for fiscal years beginning after December 15, 2022. The Company is currently evaluating the impact this new standard will have on its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which increases the
transparency and comparability of accounting for lease transactions. This ASU requires lessees to recognize liabilities for operating leases and corresponding
right-of-use assets on the balance sheet. ASU 2016-02 is effective for the Company for its fiscal year beginning after
December 15, 2021. The Company is currently evaluating the impact this new standard will have on its consolidated financial statements. Basis of Presentation Certain amounts in the prior year consolidated financial statements have been reclassified whenever necessary to conform with the current year
presentation. These reclassifications had no effect on the reported results of operations.  11




---

Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL  Notes to Consolidated Financial Statements Years Ended December 31, 2021 and 2020  3.
Loans Receivable The following table shows the composition of loans receivable, net as of December 31, 2021 and 2020:  2021


2020Revolving loans receivable

$
82,400,125


$
36,016,783Term loans receivable


601,137



4,377,837Total loans receivable


83,001,262



40,394,620Less allowance for loan losses


(836,654
)


(410,226
)Less deferred origination fees and costs, net


(561,039
)


(644,034
)Loans receivable, net

$
81,603,569


$
39,340,360  4.
Allowance for Loan Losses and Recorded Investment in Loans Receivables The following table summarizes the activity in the allowance for loan losses by loan class for the respective years ended December 31,
2021 and 2020:  BeginningBalance


Charge-Offs


Recoveries


Provisions


EndingBalance


EndingBalance:IndividuallyEvaluated forImpairment


EndingBalance:CollectivelyEvaluated forImpairmentAllowance for Loan Losses - December 31, 2021Revolving loans

$
366,448


$



$



$
464,195


$
830,643


$



$
830,643Term loans


43,778











(37,767
)


6,011



6,011



Total

$
410,226


$



$



$
426,428


$
836,654


$
6,011


$
830,643Allowance for Loan Losses - December 31, 2020Revolving loans

$
1,090,200


$



$



$
(723,752
)

$
366,448


$



$
366,448Term loans


46,277











(2,499
)


43,778



13,778



30,000Total

$
1,136,477


$



$



$
(726,251
)

$
410,226


$
13,778


$
396,448  12




---

Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL  Notes to Consolidated Financial Statements Years Ended December 31, 2021 and 2020  4.
Allowance for Loan Losses and Recorded Investment in Loans Receivablescontinued The following table presents loans receivable individually and collectively evaluated for impairment by loan class
at December 31, 2021 and 2020:  Ending Balance


Ending BalanceIndividuallyEvaluated forImpairment


Ending BalanceCollectivelyEvaluated forImpairmentLoans Receivables - December 31, 2021Revolving loans

$
82,400,125


$



$
82,400,125Term loans


601,137



601,137



Total

$
83,001,262


$
601,137


$
82,400,125Loans Receivables - December 31, 2020Revolving loans

$
36,016,783


$



$
36,016,783Term loans


4,377,837



1,377,837



3,000,000Total

$
40,394,620


$
1,377,837


$
39,016,783 The following table summarizes the non-accrual loans by loan class at
December 31, 2021 and 2020.  RecordedInvestment


UnpaidPrincipal


RelatedAllowanceLoans Receivables - December 31, 2021Term loans

$
601,137


$
601,137


$
6,011Total

$
601,137


$
601,137


$
6,011RecordedInvestment


UnpaidPrincipal


RelatedAllowanceLoans Receivables - December 31, 2020Term loans

$
1,377,837


$
1,377,837


$
13,778Total

$
1,377,837


$
1,377,837


$
13,778  13




---

Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL  Notes to Consolidated Financial Statements Years Ended December 31, 2021 and 2020  4.
Allowance for Loan Losses and Recorded Investment in Loans Receivablescontinued Credit Quality Indicators The following table summarizes the loan portfolio by the Companys internal credit rating (scale: 1 to 7) as of December 31, 2021 and
2020: Loans with a rating of 4 or better generally pose minimal risk to the Company as they exhibit, among other things, one or more of the following attributes: (1) secured collateral position; (2) satisfactory cash flows; and
(3) history of timely payment of debt obligations. Loans credit rated below 4 are considered watchlist loans; an overall degree of risk exists with these loans that warrants managements review each quarter.  December 31, 2021RevolvingLoans


Term LoansRated 4 or better

$
82,400,125


$
Rated 6






601,137Total

$
82,400,125


$
601,137December 31, 2020Rated 4 or better

$
36,016,783


$
3,000,000Rated 6






1,377,837Total

$
36,016,783


$
4,377,837  5.
Furniture and Equipment Furniture and equipment are comprised of the following at December 31, 2021 and 2020:  2021


2020Computer software and equipment

$
93,183


$
88,234Furniture and fixtures


41,032



41,032Leasehold improvement


21,551



21,551Total


155,766



150,817Less accumulated depreciation


(141,447
)


(129,717
)Furniture and equipment, net

$
14,319


$
21,100 Depreciation expense was $11,730 and $14,338 for the years ended December 31, 2021 and 2020,
respectively.  14




---

Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL  Notes to Consolidated Financial Statements Years Ended December 31, 2021 and 2020  6.
Debt On May 27, 2016, the Company entered into a four-year, non-recourse $125,000,000 secured revolving
credit facility, which is expandable to $200,000,000 under its accordion feature. On June 28, 2019, the credit facility was amended and has a maturity date of June 28, 2023. Under the terms of the credit facility, the Company has made
certain customary representations and warranties, and is required to comply with various covenants, including financial and reporting requirements and other customary requirements for similar credit facilities. The credit facility also includes
usual and customary events of default for credit facilities of this nature. Amounts available to borrow under the credit facility are also
subject to compliance with a borrowing base that applies different advance rates to different types of assets in the Companys portfolio that are pledged as collateral. As of December 31, 2021 and 2020, there were principal borrowings of
$60,000,000 and $25,000,000 outstanding, respectively, under the credit facility. As of December 31, 2021 and 2020, there were approximately $76,107,000 and $38,675,000 of eligible loans and related security pledged as collateral under the
credit facility, respectively. Interest on the credit facility accrues at a variable rate per annum of
one-month LIBOR plus 2.25% approximating 2.35% and 2.39% at December 31, 2021 and 2020, respectively. The Company also pays other customary loan fees for the credit facility. The credit facility is comprised of the following at December 31, 2021 and 2020:  2021


2020Principal borrowings

$
60,000,000


$
25,000,000Unamortized debt issuance costs


(601,622
)


(798,116
)Credit facility, net

$
59,398,378


$
24,201,884  7.
Commitments and Concentrations At December 31, 2021 and 2020, the Company has committed facilities to its borrowers totaling approximately $183,501,000 and $218,028,000,
respectively, of which approximately $100,500,000 and $177,633,000, respectively, was unused. Borrowers may borrow up to the lesser of (i) the committed facility or (ii) the underlying collateral value multiplied by the advance rate. Of
the unused committed facility amount at December 31, 2021 and 2020, borrowers could borrow up to approximately $27,414,000 and $71,292,000, respectively. As of December 31, 2021 and 2020, the Company had sufficient cash available and/or
availability under its credit facility to fund its commitments. At December 31, 2021, the Company had two loans approximating 29% and
16% of the total loans receivable and at December 31, 2020, the Company had one loan approximating 29% of the total loans receivable, respectively.  15




---

Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL  Notes to Consolidated Financial Statements Years Ended December 31, 2021 and 2020  8.
Lease Commitments The Company leases its headquarters, regional sales offices and equipment under non-cancelable
operating leases, which expire at various dates through 2024. As of December 31, 2021, future lease payments under non-cancelable operating leases, are as follows:  Years ending December 31:2022 & Thereafter

$
63,657Total

$
63,657 Total rent expense for all leases amounted to approximately $167,000 and $168,000 for the years ended
December 31, 2021 and 2020, respectively.  9.
401(k) Savings Plan The Company has a savings incentive plan covering substantially all employees of the Company. The Companys contribution for the years
ended December 31, 2021 and 2020 was approximately $134,000 and $135,000, respectively.  10.
Long-Term Incentive Plan The Company has a Long-Term Incentive Plan (LTIP Plan) that provides for an annual bonus pool to employees based on the Company
achieving certain performance criteria.  11.
Fair Value Disclosure Fair value is the exchange price that would be received for an asset or paid to transfer a liability (exit price) in the principal or most
advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. There are three levels of inputs that may be used to measure fair values: Level1: Quoted prices (unadjusted) for identical assets or liabilities in active markets that the entity has the
ability to access as of the measurement date. Level2: Significant other observable inputs other than
Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. Level3: Significant unobservable inputs that reflect a companys own assumptions about the assumptions that
market participants would use in pricing an asset or liability. The following information should not be interpreted as an estimate of the
fair value of the entire Company, since a fair value calculation is only provided for a limited portion of the Companys assets and liabilities. Assets and liabilities measured at fair value on a recurring basis are summarized in the table
below at December 31, 2021 and 2020.  16




---

Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL  Notes to Consolidated Financial Statements Years Ended December 31, 2021 and 2020  11.
Fair Value Disclosurecontinued  2021Carrying Value


Fair ValueFinancial assets:Cash and cash equivalents (Level 1)

$
3,256,256


$
3,256,256Loans receivable, net (Level 3)


81,603,569



82,020,335Financial liabilities:Credit facility, net (Level 2)


59,398,378



60,000,0002020Carrying Value


Fair ValueFinancial assets:Cash and cash equivalents (Level 1)

$
10,356,890


$
10,356,890Loans receivable, net (Level 3)


39,340,360



39,653,713Financial liabilities:Credit facility, net (Level 2)


24,201,884



25,000,000  12.
Related Parties An employee of an affiliated entity provides marketing and sales services to the Company for which the Company reimburses the affiliated
entity. Such reimbursements have been included in compensation and benefits expenses. The Company had sold a participation in a loan
agreement to SLR Investment Corp., an affiliate of SLR Senior. The loan was repaid in February 2021. The participation was sold for a total commitment of $15,000,000 and the amount outstanding at December 31, 2020 was $7,579,174.  13.
Subsequent Events The Company evaluated subsequent events for recognition or disclosure through February 18, 2022, which was the date the consolidated
financial statements were available to be issued.  17